Group Leader: Professor Peter McCluskey
Our research aims to improve patient care and outcomes in patients suffering from uveitis and inflammation, and develop effective treatment therapies and diagnostic tests.
We endeavour to improve treatment outcomes for patients suffering from uveitis and inflammation by:
– establishing multidisciplinary adult and paediatric uveitis clinics (with adult and paediatric rheumatologists)
– creating a database of patients with uveitis attending our clinics
– instituting protocol driven management for vision threatening uveitis to improve outcomes
– developing a prospective Save Sight Registry to track uveitis outcomes (FUB – Fight Uveitis Blindness).
What are the issues?
Uveitis and inflammatory eye disease are common causes of vision loss In patients of working age,
The uvea tract is the middle vascular coat of the eye and Its functions are to supply oxygen, glucose and nutrients to the eye. It also has an active Immune defence system to protect the delicate retina and other structures inside the eye.
Uveitis is a non-specific generic term for inflammation of the uveal tract of the eye (like arthritis !s a non-specific term for Inflammation of the joints).
It can be caused by many different processes, In about 60% of patients uveitis Is related to Infections such as herpes viruses, toxoplasmosls or tuberculosis, or Inflammatory disorders such as sarcoidosis, Behcet’s diease or systemic vasculitis.
In the remaining 40%, we are unable to identify a cause at this time.
Many treatments are non-specific immunosuppressive drugs rather than specific targeted therapies, and there is little understanding of outcomes of treatment.
Additionally, ocular surgery in patients with uveitis is complex.
The uveitis unit performs regular audits and clinical reviews of patients attending our clinics. Most of these become peer reviewed publications.
We widely utilise multi-modal imaging to aid in diagnosis and management. We have an active collaboration with Dr Alessandro Invernizzi from the University of Milan which is a world leading ocular imaging centre.
We have a number of active clinical research projects including:
– sarcoid related uveitis
– paraneoplastic and autoimmune retinopathy
– plaquenil toxicity
– birdshot choroidopathy
– tubercular uveitis
– local therapy for uveitis – ozurdex, anti-VEGF agents
– biologic therapy for severe uveitis.
Paediatric uveitis clinic
A multidisciplinary paediatric uveitis clinic will soon open at the Sydney Eye Hospital. where we’ll work alongside paediatric rheumatologists. We’ll be focused on patient care and outcomes in children with severe uveitis.
We have begun to establish a large DNA biobank for patients with inflammatory eye diseases at Sydney Eye Hospital. This biobank has stimulated interest in biobanking across the discipline and plans are now well advanced to establish the ocular disease focused biobank in Australia within the Discipline of Clinical Ophthalmology and Eye Health based at Sydney Eye Hospital.
We will store samples from a wide range of complex ocular disorders managed at Sydney Eye Hospital. The first patient samples are currently being collected, and validated human tissue will be readily available to answer important research questions. The biobank project aims to provide re.searchers on campus with pathologist-validated normal, diseased and surgical human eye tissue to rapidly translate observations made in vitro (in test tubes) or in animal models into therapies or diagnostic tests for humans.
Peter McCluskey is currently Professor of Clinical Ophthalmology and Eye Health at Faculty of Medicine and Health at the University of Sydney and is the Director of the Save Sight Institute at Sydney Eye Hospital. Peter McCluskey is an internationally recognised inflammatory eye disease specialist with more than 30 years experience treating patients with vision threatening inflammatory eye disease.
He is an author of more than 250 peer reviewed papers, 24 book chapters, 2 apps and 4 books. His H-index is currently 40. He is a dedicated teacher who has lectured and is a principal invited speaker at conferences around the world. Peter McCluskey has received distinguished service awards from APAO, RANZCO and AAO for his teaching contributions.
He runs the largest tertiary referral, public sector uveitis service in Australia, at Sydney Eye Hospital and is involved in clinical research, laboratory research and clinical trials. As Director of the Save Sight Institute at Sydney Eye Hospital, he has oversight of eight research groups involved in both clinical and basic eye research that encompasses the common causes of blindness such as ARMD, diabetic retinopathy, cataract, corneal disease, uveitis and genetically determined eye disease.
to Save Sight Institute’s mailing list for news and updates